Skip to main content
. 2024 Feb 4;13(2):e6979. doi: 10.1002/cam4.6979

FIGURE 2.

FIGURE 2

Kaplan Meyer Survival for the HER2‐Negative versus HER2‐Low metastatic breast cancer patients. Median survival was 41.17 (95% CI 40.34–42.12) months for HER2‐negative vs 43.7 (95% CI 43.0–44.2) months for HER2‐low patients, p‐value of 0.009.